Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
5.84
+0.32 (5.80%)
At close: Nov 13, 2026, 4:00 PM EST
5.84
0.00 (0.00%)
After-hours: Nov 13, 2026, 4:15 PM EST
Cytek Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 207.65 | 201.49 | 200.45 | 193.02 | 164.04 | 127.95 | |
Revenue Growth | 5.50% | 0.52% | 3.85% | 17.67% | 28.20% | 37.82% |
Cost of Revenue | 96.76 | 97.03 | 89.35 | 83.59 | 63.06 | 48.81 |
Gross Profit | 110.89 | 104.46 | 111.11 | 109.43 | 100.97 | 79.14 |
Selling, General & Admin | 119.9 | 108.38 | 92.23 | 93.12 | 67.92 | 45.55 |
Research & Development | 37.66 | 36.47 | 39.4 | 44.15 | 34.86 | 24.44 |
Operating Expenses | 157.57 | 144.84 | 131.63 | 137.27 | 102.78 | 69.99 |
Operating Income | -46.68 | -40.38 | -20.52 | -27.85 | -1.8 | 9.16 |
Interest Expense | -0.08 | -0.47 | - | -2.07 | -2.57 | -1.74 |
Interest & Investment Income | 3.21 | 2.22 | 10.36 | 6.41 | 4.62 | 0.05 |
Earnings From Equity Investments | - | - | - | - | 0.04 | 0.04 |
Currency Exchange Gain (Loss) | -3.6 | 0.7 | -3.6 | - | - | -1.57 |
Other Non Operating Income (Expenses) | 5.99 | 8.1 | 8.06 | 7.79 | 0.98 | - |
EBT Excluding Unusual Items | -41.16 | -29.84 | -5.7 | -15.71 | 1.26 | 5.94 |
Pretax Income | -39.96 | -29.84 | -5.7 | -15.71 | 1.26 | 5.94 |
Income Tax Expense | 41.24 | 36.7 | 0.32 | -3.56 | -1.22 | 2.91 |
Earnings From Continuing Operations | -81.2 | -66.54 | -6.02 | -12.15 | 2.48 | 3.03 |
Minority Interest in Earnings | - | - | - | - | 0.09 | 0.03 |
Net Income | -81.2 | -66.54 | -6.02 | -12.15 | 2.58 | 3.05 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 3 |
Net Income to Common | -81.2 | -66.54 | -6.02 | -12.15 | 2.58 | 0.05 |
Net Income Growth | - | - | - | - | 4853.85% | -98.38% |
Shares Outstanding (Basic) | 129 | 128 | 131 | 135 | 135 | 77 |
Shares Outstanding (Diluted) | 129 | 128 | 131 | 135 | 139 | 82 |
Shares Change | 0.94% | -2.19% | -3.45% | -2.37% | 69.93% | 150.13% |
EPS (Basic) | -0.63 | -0.52 | -0.05 | -0.09 | 0.02 | 0.00 |
EPS (Diluted) | -0.63 | -0.52 | -0.05 | -0.09 | 0.02 | 0.00 |
EPS Growth | - | - | - | - | 2906.28% | -99.36% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -13.48 | -8.77 | 21.85 | 0.63 | -21.98 | 0.27 |
Free Cash Flow Per Share | -0.10 | -0.07 | 0.17 | 0.01 | -0.16 | 0.00 |
Gross Margin | 53.40% | 51.84% | 55.43% | 56.69% | 61.56% | 61.86% |
Operating Margin | -22.48% | -20.04% | -10.24% | -14.43% | -1.10% | 7.16% |
Profit Margin | -39.10% | -33.02% | -3.00% | -6.29% | 1.57% | 0.04% |
Free Cash Flow Margin | -6.49% | -4.35% | 10.90% | 0.33% | -13.40% | 0.21% |
EBITDA | -38.8 | -32.81 | -13.31 | -21.8 | 0.69 | 10.4 |
EBITDA Margin | -18.68% | -16.28% | -6.64% | -11.29% | 0.42% | 8.13% |
D&A For EBITDA | 7.88 | 7.58 | 7.21 | 6.05 | 2.49 | 1.24 |
EBIT | -46.68 | -40.38 | -20.52 | -27.85 | -1.8 | 9.16 |
EBIT Margin | -22.48% | -20.04% | -10.24% | -14.43% | -1.10% | 7.16% |
Effective Tax Rate | - | - | - | - | - | 49.02% |
Revenue as Reported | 207.65 | 201.49 | 200.45 | 193.02 | 164.04 | 127.95 |